利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.061 秒)

    Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
    1.
    发明授权
    Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof 失效
    四唑衍生物及其代谢相关病症的治疗方法

    公开(公告)号：US08637555B2

    公开(公告)日：2014-01-28

    申请号：US10535345

    申请日：2004-10-29

    申请人： Graeme Semple ,  Thomas Schrader ,  Philip J. Skinner ,  Steven L. Colletti ,  Tawfik Gharbaoui ,  Jason E. Imbriglio ,  Jae-Kyu Jung ,  Rui Liang ,  Subharekha Raghavan ,  Darby Schmidt ,  James R. Tata

    发明人： Graeme Semple ,  Thomas Schrader ,  Philip J. Skinner ,  Steven L. Colletti ,  Tawfik Gharbaoui ,  Jason E. Imbriglio ,  Jae-Kyu Jung ,  Rui Liang ,  Subharekha Raghavan ,  Darby Schmidt ,  James R. Tata

    IPC分类号： A61K31/407 ,  C07D231/54

    CPC分类号： C07D491/04 ,  C07D403/04 ,  C07D495/04

    摘要： The present invention relates to certain tetrazole derivatives of Formula (I), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.

    摘要翻译： 本发明涉及式（I）的某些四唑衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，2型糖尿病 ，综合征-X等。 此外，本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成 抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂等。

    Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
    2.
    发明授权
    Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof 有权
    融合的吡唑衍生物及其代谢相关病症的治疗方法

    公开(公告)号：US07241792B2

    公开(公告)日：2007-07-10

    申请号：US11315753

    申请日：2005-12-22

    申请人： P. Douglas Boatman ,  Thomas O. Schrader ,  Graeme Semple ,  Philip J. Skinner ,  Jae-Kyu Jung

    发明人： P. Douglas Boatman ,  Thomas O. Schrader ,  Graeme Semple ,  Philip J. Skinner ,  Jae-Kyu Jung

    IPC分类号： A61K31/407 ,  C07D231/54

    CPC分类号： C07D403/04 ,  C07D209/80 ,  C07D209/88 ,  C07D231/54 ,  C07D265/36 ,  C07D471/04 ,  C07D471/14

    摘要： The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.

    摘要翻译： 本发明涉及式（Ia）的某些稠合吡唑衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，2型糖尿病的方法 ，综合征-X等。 此外，本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成 抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂，DP受体拮抗剂等。

    3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
    5.
    发明授权
    3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders 失效
    可用于治疗GPR81受体疾病的3H-咪唑并[4,5-b]吡啶-5-醇衍生物

    公开(公告)号：US08507473B2

    公开(公告)日：2013-08-13

    申请号：US13063305

    申请日：2009-09-10

    申请人： P. Douglas Boatman ,  Benjamin R. Johnson ,  Jae-Kyu Jung ,  Michelle Kasem ,  Thomas O. Schrader ,  Philip J. Skinner ,  Steven Colletti

    发明人： P. Douglas Boatman ,  Benjamin R. Johnson ,  Jae-Kyu Jung ,  Michelle Kasem ,  Thomas O. Schrader ,  Philip J. Skinner ,  Steven Colletti

    IPC分类号： C07D471/04 ,  A61K31/437 ,  A61K31/55 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10

    CPC分类号： C07D471/04

    摘要： The present invention is directed to certain 3H-imidazo[4,5-b]pyridin-5-ol derivatives of Formula (Ia) and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists of the GPR81 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of GPR81 associated disorders, for example, dyslipidemia, atherosclerosis, atheromatous disease, hypertension, coronary heart disease, stroke, insulin resistance, impaired glucose tolerance, type 2 diabetes, syndrome X, obesity, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type 1 diabetes and acne.

    摘要翻译： 本发明涉及式（Ia）的某些3H-咪唑并[4,5-b]吡啶-5-醇衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如GPR81受体的激动剂。 本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗GPR81相关疾病例如血脂异常，动脉粥样硬化，动脉粥样硬化疾病，高血压，冠心病， 中风，胰岛素抵抗，葡萄糖耐量异常，2型糖尿病，X综合征，肥胖症，牛皮癣，类风湿性关节炎，克罗恩病，移植排斥反应，多发性硬化，系统性红斑狼疮，溃疡性结肠炎，1型糖尿病和痤疮。

    Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
    7.
    发明授权
    Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof 有权
    融合的吡唑衍生物及其代谢相关病症的治疗方法

    公开(公告)号：US07612106B2

    公开(公告)日：2009-11-03

    申请号：US11601184

    申请日：2006-11-17

    申请人： P. Douglas Boatman ,  Thomas O. Schrader ,  Graeme Semple ,  Philip J. Skinner ,  Jae-Kyu Jung

    发明人： P. Douglas Boatman ,  Thomas O. Schrader ,  Graeme Semple ,  Philip J. Skinner ,  Jae-Kyu Jung

    IPC分类号： A61K31/407 ,  C07D231/54

    CPC分类号： C07D403/04 ,  C07D209/80 ,  C07D209/88 ,  C07D231/54 ,  C07D265/36 ,  C07D471/04 ,  C07D471/14

    摘要： The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.

    摘要翻译： 本发明涉及式（Ia）的某些稠合吡唑衍生物及其药学上可接受的盐，其表现出有用的药理学性质，例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物，以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常，动脉粥样硬化，冠心病，胰岛素抵抗，2型糖尿病的方法 ，综合征-X等。 此外，本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类，醛糖还原酶抑制剂，双胍类，HMG-CoA还原酶抑制剂，角鲨烯合成 抑制剂，贝特类，LDL分解代谢增强剂，血管紧张素转换酶（ACE）抑制剂，胰岛素分泌增强剂，DP受体拮抗剂等。